These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31952572)

  • 1. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
    Ponnusamy L; Mahalingaiah PKS; Singh KP
    Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.
    Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
    Cancer Drug Resist; 2019; 2(2):297-312. PubMed ID: 35582717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
    Strauss J; Figg WD
    Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
    Kim JJ; Rai R
    Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms.
    Mora Y; Reyes ME; Zanella L; Mora B; Buchegger K; Ili C; Brebi P
    Pharmacogenomics; 2021 Aug; 22(12):777-790. PubMed ID: 34281355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
    Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E
    Drug Resist Updat; 2011 Dec; 14(6):280-96. PubMed ID: 21955833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bitter side of epigenetics: variability and resistance to chemotherapy.
    Hajji N; García-Domínguez DJ; Hontecillas-Prieto L; O'Neill K; de Álava E; Syed N
    Epigenomics; 2021 Mar; 13(5):397-403. PubMed ID: 29932342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance.
    Guo L; Lee YT; Zhou Y; Huang Y
    Semin Cancer Biol; 2022 Aug; 83():487-502. PubMed ID: 33421619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance.
    Zhou Y; Sun W; Qin Z; Guo S; Kang Y; Zeng S; Yu L
    Biochem Pharmacol; 2021 Jul; 189():114228. PubMed ID: 32976832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidrugs: targeting epigenetic marks in cancer treatment.
    Miranda Furtado CL; Dos Santos Luciano MC; Silva Santos RD; Furtado GP; Moraes MO; Pessoa C
    Epigenetics; 2019 Dec; 14(12):1164-1176. PubMed ID: 31282279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance.
    Fatma H; Maurya SK; Siddique HR
    Semin Cancer Biol; 2022 Aug; 83():166-176. PubMed ID: 33220458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
    Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
    Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Targeting of Platinum Resistant Testicular Cancer.
    Sonnenburg D; Spinella MJ; Albany C
    Curr Cancer Drug Targets; 2016; 16(9):789-795. PubMed ID: 26694252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
    Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
    Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we use epigenetics to prime chemoresistant lymphomas?
    Amengual JE
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):85-94. PubMed ID: 33275728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets for epigenetic therapy of cancer.
    Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
    Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer.
    Cartron PF; Cheray M; Bretaudeau L
    Epigenomics; 2020 Jan; 12(2):171-177. PubMed ID: 31849240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.